AurimMed Pharma’s innovative R&D strategy utilizes a proprietary knowledge-base referred to as the Privileged Structure Platform (PSP). The PSP consists of a compilation of thousands of carefully selected chemical structures (scaffolds) and substructures derived from clinically successful drugs. A great deal is already known about these chemical structures regarding their absorption, distribution, metabolism, excretion, and toxicology (ADMET). Skillful modification and recombination of the structural features of PSP entries serves as the starting point for the creation of completely novel scaffolds and candidate compounds. Because AurimMed’s drug design process begins with physiologically and clinically acceptable scaffolds, this efficient and proven strategic approach offers the potential for decreased toxicity and a greatly increased probability of successful regulatory approval. Although AurimMed’s research programs start with familiar chemical backbones, the resulting novel and proprietary compositions often have new modes or mechanisms of action.
AurimMed’s portfolio of novel, proprietary products targeted for the treatment of central nervous system (CNS) disorders, particularly epilepsy (including the lead drug candidate, AMP-X-0079), has been designed and developed using the PSP.